4:31 pm Pacira Pharma announced additional Phase 3 data supporting the efficacy and safety of EXPAREL to achieve a femoral nerve block in patients undergoing total knee arthroplasty; sNDA submission expected in Q2 2014
View todays social media effects on PCRX
View the latest stocks trending across Twitter. Click to view dashboard
See who Pacira is hiring next, click here to view
